

May 6, 2022

Company name: FINDEX Inc  
Name of representative: Teruo Aibara, President & CEO  
(Securities code: 3649; PRIME Market)  
Inquiries: Atsushi Fujita, Director and Head of Administration  
(Telephone: +81-89-947-3388)

## Strategic Alliance with Toyota Tsusho Corporation

At an extraordinary meeting of the Board of Directors held on May 6, 2022, the Company resolved to enter into a strategic partnership agreement with Toyota Tsusho Corporation ((hereafter referred to as "Toyota Tsusho") regarding medical information system business and health tech business and entered into the agreement on the same date.

### 1. Reason for Alliance

With our goal of "Toward better health and wellbeing of all people" we have delivered a lot of healthcare organizations with integrated digital solutions, which realize their centralized management and effective utilization of test data and document data. Also, leveraging our nurtured technology and trust, we, ourself, invented, developed, manufactured, and sold gaze analyzing perimeter which adopts a completely new testing principle.

Towards better society, at such a momentous time, we are committed to improve the convenience and efficiency of medical exam at healthcare organizations overseas, as well as early detection of optical diseases, and educational activities in Japan, in collaboration with Toyota Tsusho, who has built up relationships of trust through their wide variety of businesses around the world.

### 2. Area for Alliance

The Company and Toyota Tsusho will cooperate under an exclusive sales agreement mainly for the following solutions.

#### (i) Overseas sales of medical information solutions

As the geographical strategies, we will sell medical information platform, mainly our flagship product "Claio" (image filing system), to key healthcare organizations in India and the ASEAN region. We will establish a cordial support system in collaboration with local medical system companies to ensure efficient and sustainable delivery of our product and service. In June 2022, we will introduce Claio, on a trial basis, to Sakra World Hospital in India, which Toyota Tsusho has its investment stake, and begin test operations.

With a population of over 1.3 billion, the healthcare market of India has an unprecedented scalability, and at the same time, there remain a lot of issues that can be ameliorated by digitalization. Addressing challenges to solve issues out there, we will contribute to the realization of a sustainable society by improving the quality of medical care and the efficiency of hospital management.

#### (ii) Introduction of "GAP-screener" (gaze analyzing perimeter/regulatory product) to health checkup facilities in Japan

"GAP-screener", which was commercialized for optional use during health checkups, will be introduced to domestic health checkup facilities and multiphasic health screening facilities under Toyota Tsusho's sales strategy. This product is our original invention, darkroom-free, objective optical testing device.

By permanently exhibiting this solution other than ophthalmology facilities, more convenient testing will be enabled, leading to the early detection of glaucoma. We will also utilize the visual field data obtained through the test, for various possibilities in future research and development in the medical field, such as the establishment of new treatment methods.

### 3. Corporate Profile of Strategic Alliance Partner

① Corporate Name	Toyota Tsusho Corporation		
② Location (head office)	9-8, Meieki 4-chome, Nakamura-ku, Nagoya		
③ President & CEO	Ichiro Kashitani		
④ Business	General trading and business investment company, engaged in metal, parts and logistics, automotive, machinery, energy and project, chemical and electronics, food and consumer services, etc.		
⑤ Capital	64,936 million yen		
⑥ Establishment	July 1, 1948		
⑦ Major Shareholders	TOYOTA MOTOR CORPORATION 21.69% The Master Trust Bank of Japan, Ltd. (Trust Account) 13.56% TOYOTA INDUSTRIES CORPORATION 11.18% (As of September 30, 2021)		
⑧ Relationship with our Group	Capital, human, transaction, related parties	N/A	
⑨ Recent three-year performance and financial status	(JPY in 100 million)		
Fiscal year	2019	2020	2021
Total asset	44,414	45,452	52,280
Net asset	13,896	13,724	16,580
Gross profit	6,384	6,398	6,076
Operating income	2,151	2,103	2,130
Income before tax	2,291	2,248	2,214
Net income	1,326	1,355	1,346
EPS (JPY)	376.89	385.25	382.56
DOE (JPY)	100	110	112

### 4. Schedule

Date of resolution at Board of Director : May 6, 2022

Date of alliance agreement : May 6, 2022

Date of the commencement of business : May 6, 2022

### 5. Outlook

The impact of this strategic alliance on our performance is currently under inspection, we believe that this alliance will significantly contribute to our corporate value enhancement in the medium to long term. In a timely manner, we will appropriately announce any matters that should be disclosed.